Anna-Maria Hoffmann-Vold, M.D., Ph.D.

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved, exploring how they could address key unmet needs, improve patient outcomes, and optimize healthcare resource utilization.

Panelists provide an overview of emerging therapies for progressive pulmonary fibrosis (PPF), highlighting the latest developments and potential treatment options.

Panelists discuss the key gaps and unmet needs in current management strategies for progressive pulmonary fibrosis (PPF) and how ongoing research and collaborative efforts may help address these challenges.

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses the current treatment landscape for progressive pulmonary fibrosis, highlighting nonpharmacological and pharmacological options to manage the disease.

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses how progressive pulmonary fibrosis is diagnosed in clinical practice, the barriers hindering early diagnosis, strategies to overcome these challenges and the critical role of early detection and intervention in improving patient outcomes and reducing long-term healthcare costs.

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses the most common symptoms of progressive pulmonary fibrosis (PPF), how they typically evolve and the impact of PPF on patients’ daily activities and quality of life as the disease progresses.

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses progressive pulmonary fibrosis, its primary causes and the key risk factors contributing to its development and progression.